Use of bedaquiline and delamanid in diabetes patients: clinical and pharmacological considerations
Minhui Hu,1 Chunlan Zheng,1 Feng Gao2 1Department of Internal Medicine – Section 5, Wuhan Pulmonary Hospital (Wuhan Tuberculosis Control Institute), 2Department of Endocrinology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People&rsquo...
Main Authors: | Hu MH, Zheng CL, Gao F |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2016-12-01
|
Series: | Drug Design, Development and Therapy |
Subjects: | |
Online Access: | https://www.dovepress.com/use-of-bedaquiline-and-delamanid-in-diabetes-patients-clinical-and-pha-peer-reviewed-article-DDDT |
Similar Items
-
Interim treatment outcomes in multidrug-resistant tuberculosis patients treated sequentially with bedaquiline and delamanid
by: Hoon Hee Lee, et al.
Published: (2020-09-01) -
The endTB observational study protocol: treatment of MDR-TB with bedaquiline or delamanid containing regimens
by: Uzma Khan, et al.
Published: (2019-08-01) -
Prevalence of Mycobacterium tuberculosis resistant to bedaquiline and delamanid in China
by: Wencong He, et al.
Published: (2021-09-01) -
Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug-Resistant Tuberculosis
by: Andrey Maryandyshev, et al.
Published: (2017-10-01) -
Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in Children: The Role of Bedaquiline and Delamanid
by: Francesco Pecora, et al.
Published: (2021-05-01)